Early administration of the GIP receptor antagonist (Pro3)GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity.

Autoria(s): Flatt, P.R.; Irwin, N.; McClean, P.L.; Green, Brian; Gault, V.A.; Bailey, C.J.; O'Harte, F.P.M.
Data(s)

2006
Identificador

http://pure.qub.ac.uk/portal/en/publications/early-administration-of-the-gip-receptor-antagonist-pro3gip-counters-development-of-hyperglycaemia-glucose-intolerance-and-insulin-resistance-in-genetic-obesity(d95f6def-07a8-40f6-a9ad-bd4f702be9d4).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Flatt , P R , Irwin , N , McClean , P L , Green , B , Gault , V A , Bailey , C J & O'Harte , F P M 2006 , ' Early administration of the GIP receptor antagonist (Pro3)GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity. ' Diabetologia , vol 49 , no. S1 , pp. 108 .
Tipo

article
Acesso ao item digital